Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Post-transplant maintenance strategies in AML

Arnon Nagler • 14 Jun 2021
EHA 2021
Acute Myeloid Leukemia Leukemia Gilteritinib Sorafenib Venetoclax

Arnon Nagler, MD, Chaim Sheba Medical Center, Tel-Aviv, Israel, discusses post-transplant maintenance strategies for patients with acute myeloid leukemia (AML), in particular highlighting recommendations from the Acute Leukemia Working Party on sorafenib for patients with mutant FLT3. Prof. Nagler also discusses preventative therapy with donor lymphocyte infusion (DLI) and the role of gilteritinib post-transplant. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Arnon Nagler

2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:21
Trends in alloSCT for good-risk AML: a longitudinal study
Arnon Nagler • 9 Dec 2023
2:15
GvHD prophylaxis post-alloSCT: PTCy versus ATG
Arnon Nagler • 9 Dec 2023
2:13
Haploidentical SCT for the treatment of secondary AML
Arnon Nagler • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals